To the Editor, We read with interest the study by Nagler and colleagues comparing peripheral blood stem cells (PBSC) versus bone marrow (BM) as a graft source for non-T-depleted haploidentical allogeneic hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) in patients with secondary acute myeloid leukemia in first complete remission [1].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Arjun D.
Contact Arjun D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack